94
Erβ agonist_NASH
The Ohio State University
Small molecule
Metabolic disease
Hit To Lead or Lead Optimization
Non-alcoholic steatohepatitis (NASH) is projected to affect over 18 million people annually by 2027 and is set to eclipse hepatitis B virus (HBV) as the leading cause of hepatocellular carcinoma. NASH is associated not only with liver cancer but also cirrhosis and multiple other chronic health complications. New selective estrogen receptor modulators (SERMs) selectively agonizing ERβ have been developed by researchers at The Ohio State University. These new compounds have the potential to meet the need for a truly effective drug in this new “epidemic” indication that has so far been nearly untreatable.
PCT-US2016-052531